Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

13.58
-3.3200-19.64%
Post-market: 13.920.3425+2.52%19:30 EDT
Volume:1.18M
Turnover:16.97M
Market Cap:155.18M
PE:-1.99
High:15.50
Open:15.48
Low:13.30
Close:16.90
52wk High:17.40
52wk Low:4.86
Shares:11.43M
Float Shares:9.08M
Volume Ratio:4.24
T/O Rate:12.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.65
PE(LYR):-1.10

Loading ...

U.S. Stocks on the MOVE-Halliburton, BioNTech, Kazia Therapeutics

Reuters
·
Aug 29

Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Kazia Therapeutics (KZIA) and Cerus (CERS)

TIPRANKS
·
Aug 28

Kazia Therapeutics Limited Announces Pricing of up to $120 Million Public Offering

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics Ltd: Files to Offer up to $80 Mln of American Depositary Shares Representing Ordinary Shares- SEC Filing

THOMSON REUTERS
·
Aug 28

Kazia Slides After Breast Cancer Drug Update, Equity Offering Launch

Reuters
·
Aug 28

Kazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment

TIPRANKS
·
Aug 28

Kazia Therapeutics announces offering of ADS, warrants

TIPRANKS
·
Aug 28

Kazia Therapeutics Launches Tranched Registered Public Offering of ADSs, Warrants

Reuters
·
Aug 28

Kazia Therapeutics Limited Announces Proposed Public Offering

THOMSON REUTERS
·
Aug 28

Kazia Says Paxalisib Posts 100% Clinical Benefit Rate in Six-Patient Phase 1b Metastatic TNBC Study

Reuters
·
Aug 28

Kazia Therapeutics - Reports 83% Objective Response Rate in Six Patients

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - Phase 1B Study Enrollment Expected to Complete by July 2027, with Interim Clinical Updates Anticipated Throughout 2026 and 2027

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - All Patients Show Median 83% Reduction in Ctc Clusters, 51% in Exhausted T Cells

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics - no Treatment-Related Serious Adverse Events Observed

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer

THOMSON REUTERS
·
Jul 28

Kazia Therapeutics Ltd : Btig Initiates Coverage with Buy Rating; Price Target $34

THOMSON REUTERS
·
Jul 01

Kazia Therapeutics CFO James Levine files initial beneficial ownership statement

Reuters
·
Jun 16

ADRs Advance; 111 Inc. Climbs 14%

Dow Jones
·
Jun 13

Kazia Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
Jun 11

Kazia Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
Jun 11